Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia

NCT01518517 is registered in ClinicalTrials.gov with ERYtech Pharma as lead sponsor.

NCT NCT01518517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01518517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia
Lead sponsor
ERYtech Pharma
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2009
Completion date
October 31, 2016
Enrollment
85 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, in relapse